{
  "slug": "velorum-therapeutics",
  "name": "Velorum Therapeutics",
  "yc_id": 29429,
  "batch": "Winter 2024",
  "website": "https://www.velorumtx.com/",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:29:24.302972",
    "website": "https://www.velorumtx.com/",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 3116.79,
      "final_url": "https://www.velorumtx.com/",
      "redirected": false,
      "checked_at": "2025-10-17T01:29:27.419774"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "velorumtx.com",
      "registrar": "Squarespace Domains II LLC",
      "creation_date": "2023-03-14T21:19:13",
      "expiration_date": "2026-03-14T21:19:13",
      "domain_age_days": 947,
      "domain_age_years": 2.6,
      "name_servers": [
        "NS-CLOUD-B1.GOOGLEDOMAINS.COM",
        "NS-CLOUD-B2.GOOGLEDOMAINS.COM",
        "NS-CLOUD-B3.GOOGLEDOMAINS.COM",
        "NS-CLOUD-B4.GOOGLEDOMAINS.COM"
      ]
    },
    "social_links": {
      "twitter": "https://x.com/velorumtx",
      "linkedin": "https://www.linkedin.com/company/velorumtx",
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": true,
      "content_security_policy": false,
      "x_frame_options": false,
      "x_content_type_options": false,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 16,
      "server": "Unknown"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:41:27.997162",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0-claude",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T10:55:06.598658",
    "market_analysis": {
      "market_size": "large",
      "market_stage": "emerging",
      "key_trends": [
        "Growing focus on rare disease therapeutics",
        "Advances in heme biology understanding",
        "Increased investment in precision medicine"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Deep scientific expertise in heme biology - a specialized and complex area with high barriers to entry",
      "differentiation": "Novel approach targeting heme biology pathways for therapeutic intervention",
      "competitive_advantages": [
        "First-mover advantage in heme-focused therapeutics",
        "Specialized scientific knowledge base"
      ],
      "competitive_vulnerabilities": [
        "Small team size limiting R&D capacity",
        "Dependence on niche scientific expertise"
      ]
    },
    "business_model": {
      "revenue_model": "pharmaceutical licensing and royalties",
      "scalability": "high",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Y Combinator backing",
        "Established web presence for 2+ years"
      ],
      "growth_bottlenecks": [
        "Long drug development timelines",
        "Regulatory approval requirements"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 8,
      "key_risks": [
        "Clinical trial failures",
        "Regulatory approval challenges",
        "Competition from larger pharma companies"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Novel therapeutic approach",
        "Large addressable market",
        "Y Combinator validation"
      ],
      "concerns": [
        "High capital requirements",
        "Long development timeline"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Alnylam Pharmaceuticals",
        "Moderna"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Secure Series A funding",
        "Expand scientific team"
      ],
      "expansion_opportunities": [
        "Partnership with larger pharma companies",
        "Multiple indication development"
      ]
    },
    "tokens_used": {
      "input": 654,
      "output": 511,
      "total": 1165,
      "estimated_cost": 0.009627
    },
    "status": "success"
  },
  "phase8_complete": true
}